YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
TORONTO, Oct. 1, 2026 /CNW/ -- Aimia Inc. (TSX: AIM) (JSE: AII) (AIM: AII) ("the Company") is pleased to announce the admission of its common shares to trading on the AIM market of the London Stock Exchange, and dealings will commence toda…
Nvidia's record A$150b share buyback plan has put a bright global spotlight on AI hardware and software, and Australian AI players are riding that wave of attention. When a giant commits that much capital, it signals how seriously industry…
Rising global bond yields have pushed up borrowing costs and rattled high growth sectors, yet the world's biggest tech leaders are still gathering to discuss artificial intelligence with political heavyweights. That gap between short term…
AIM ImmunoTech Inc. Company CEO outlines the differentiated mechanism and clinical potential of Ampligen in pancreatic cancer Survival data highlighted in accompanying chart show Ampligen-associated median overall survival of 34.8 months i…
TORONTO, Sept. 1, 2026 /CNW/ -- Aimia Inc. (TSX: AIM) (JSE: AII) announced today that it repurchased and settled for cancellation a total of 97,150 of its common shares in the month of August 2026 under the Company's normal course issuer b…
TORONTO, Aug. 11, 2026 /CNW/ -- Aimia Inc. (TSX: AIM) (JSE: AII) ("Aimia" or the "Company"), today reported its financial results for the three and six months ended June 30, 2026. All amounts are in Canadian currency unless otherwise noted…
AIM ImmunoTech Inc. Milestone Advances Ampligen® Toward Key Clinical Benefit Readout in December 2026 and Overall Survival Analysis in Mid-2027 OCALA, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM"…
For Immediate Release Chicago, IL – July 24, 2026 – Stocks in this week's article are AIM ImmunoTech AIM, Hasbro HAS, Fox FOX, Cencora Inc. COR and Intuitive Surgical ISRG. Bet on 5 Top-Ranked Stocks with Rising P/E Ratios Investors often…
Investors often opt for the stock-picking approach that involves stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind this i…
AIM ImmunoTech Inc. CEO Thomas Equels discusses recent clinical progress, upcoming milestones and the Company's commitment to advancing Ampligen® for patients with pancreatic cancer Access it here OCALA, Fla., July 07, 2026 (GLOBE NEWSWIRE…
AIM ImmunoTech Inc. Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity OCALA, Fla., June…
(RTTNews) - AIM ImmunoTech Inc. (AIM), an immuno-pharma company, announced that the final subject have received their first dose in the Phase 2 DURIPANC clinical trial evaluating its lead investigational drug, Ampligen (rintatolimod), in c…
AIM ImmunoTech Inc. Study results expected to support design and initiation of a pivotal Phase 3 clinical trial in the treatment of metastatic pancreatic cancer OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE Ameri…
OCALA, Fla., June 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final subject has received their first dose in the Phase 2 DURIPANC clinical trial evaluating Amplige…
Investors often opt for an investment approach that involves picking stocks with a low price-to-earnings (P/E) ratio. This strategy is based on the notion that the lower the P/E ratio is, the higher the stock value. The reasoning behind th…
OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive progress in a mid-year update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen®…
AIM ImmunoTech Inc. Company remains on track for a planned December 2026 evaluation of the clinical trial’s primary endpoint OCALA, Fla., June 08, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) t…
Video segment examines current Ebola outbreak concerns, unmet need surrounding the Bundibugyo strain and Ampligen’s previously published antiviral research Discussion highlights Ampligen’s immune-modulating mechanism, prior Biosafety Level…
(RTTNews) - Pre-market trading is offering an early glimpse into biotech stocks likely to attract investor attention this Wednesday. Significant price moves ahead of the opening bell are being driven by clinical trial updates, public and p…
(RTTNews) - Biotech stocks are showing strong pre-market moves this Tuesday, hinting at possible breakout setups. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket Gainers On Tuesd…
(RTTNews) - Biotech companies are seeing significant pre-market activity this Monday, suggesting potential breakout opportunities. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket…
AIM ImmunoTech Inc. Final Subject Meets Enrollment Criteria and is Scheduled for Mid-June Treatment, More Than One Month Ahead of Original Target OCALA, Fla., June 01, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM…
Previously published Biosafety Level 4 pre-clinical study showed 100% survival with early treatment following infection in a mouse model following lethal doses of Ebola Company to release Virtual Investor “Ebola: What This Means” Segment o…
(RTTNews) - AIM ImmunoTech Inc. (AIM), an immuno-pharma company, announced that it has entered into definitive agreements for a registered direct offering of 7.51 million shares at a purchase price of $0.325 per share. The gross proceeds t…
OCALA, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”, today announced that it has entered into definitive agreements for a registered direct offering priced at-the-market under NYSE…
Key Points Interested in Aimia Inc.? Here are five stocks we like better. Aimia expects to close the Bozzetto sale by the end of May, after receiving the needed regulatory approvals. The transaction should generate about CAD 267 million in…
Positive Data from Named Patient Program and Positive Interim Data from Ongoing Phase 2 Clinical Trial Segment featuring Professor Doctor Casper H.J. van Eijck, Professor and Pancreato-biliary Surgeon at Erasmus MC and an oncology consulta…
On Wednesday, Aimia (TSX:AIM) discussed first-quarter financial results during its earnings call. The full transcript is provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please…
Companies Reporting Before The Bell • Similarweb (NYSE:SMWB) is estimated to report quarterly earnings at $0.01 per share on revenue of $72.97 million. • Dominari Holdings (NASDAQ:DOMH) is projected to report earnings for its first quarter…
AIM ImmunoTech Inc. Final UPMC Primary Endpoint Report Details Positive Data from Ovarian Cancer Clinical Trial Combining Ampligen, Pembrolizumab and Cisplatin Robert P. Edwards, MD, McCall Chair of Obstetrics, Gynecology, and Reproductive…
紐約, April 14, 2026 (GLOBE NEWSWIRE) -- 全球領先的人工智能 (AI) 語言技術和即時字幕解決方案供應商 AI-Media，今天在 2026 年美國廣播電視展 (NAB Show 2026) 宣佈推出兩款新世代編碼器——LEXI Text Encoder 及 LEXI Voice Encoder。 此乃公司十多年來首次推出全新編碼器硬件，這一里程碑延續 AI-Media 業界黃金標準 Encoder Pro (HD592) 的成功，繼續獲…
นิวยอร์ก, April 14, 2026 (GLOBE NEWSWIRE) -- AI‑Media ผู้นำระดับโลกด้านเทคโนโลยีภาษาอัจฉริยะและโซลูชันไลฟ์แคปชัน ประกาศเปิดตัวเอนโค้ดเดอร์เจเนอเรชันใหม่สองรุ่น ได้แก่ LEXI Text Encoder และ LEXI Voice Encoder ที่งาน NAB Show 2026 การเปิดตัว…
NUEVA YORK, April 14, 2026 (GLOBE NEWSWIRE) -- AI-Media, líder global en tecnología de lenguaje basada en inteligencia artificial y soluciones de subtitulado en vivo, anunció hoy el lanzamiento de dos nuevos codificadores de próxima genera…
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- AI-Media, líder global em tecnologia de linguagem e soluções de legendagem ao vivo alimentada por IA, anunciou hoje o lançamento de dois novos codificadores da última geração - o LEXI Text Encod…
NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- AI-Media, peneraju global dalam teknologi bahasa berkuasa AI dan penyelesaian sari kata langsung, hari ini mengumumkan pelancaran dua pengekod generasi baharu - LEXI Text Encoder dan LEXI Voice…
ニューヨーク発, April 15, 2026 (GLOBE NEWSWIRE) -- AIを活用した言語技術およびライブキャプションソリューションのグローバルリーダーであるエイアイメディア (AI-Media) は本日、NABショー (NAB Show) 2026にて、2つの新しい次世代エンコーダーであるレクシ・テキストエンコーダー (LEXI Text Encoder) およびレクシ・ボイスエンコーダー (LEXI Voice Encoder) の発売を発表した。同社が…